Christina Anderson, MD
Interventional Cardiology · Lake Forest, ILNPI 1568846434
Payments from drug & device makers
What this record shows
This record is dominated by grants: $32,000 of the $50,983 with a category attached, or 62.8%. 25 manufacturers reported payments, led by Medtronic at 53.7% of the total. Reporting peaked in 2022 at $35,695 and has fallen 87.8% since, to $4,370 in 2025.
Across 205 payments — averaging $248.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$27K
- Abbott$12K
- Edwards Lifesciences$7K
- Boston Scientific$1K
- Abiomed$696
- Shockwave Medical, Inc$565
- plus $2K from 19 others
What the payments were for
- Grants$32,00063%
- Travel & lodging$7,31614%
- Food & beverage$11,46522%
- Education$2020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 58 | $27,381 |
| Abbott | 17 | $11,754 |
| Edwards Lifesciences | 53 | $7,418 |
| Boston Scientific | 25 | $1,042 |
| Abiomed | 12 | $696 |
| Shockwave Medical, Inc | 11 | $565 |
| Biosense Webster, Inc. | 2 | $287 |
| Cardiva Medical, Inc. | 3 | $210 |
| Terumo Medical Corporation | 3 | $181 |
| ZOLL Circulation Inc | 1 | $154 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Teleflex LLC | 2 | $148 |
| Inari Medical, Inc. | 4 | $143 |
| Philips North America LLC | 2 | $135 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Pfizer | 1 | $121 |
| Johnson & Johnson | 1 | $118 |
| Amgen | 1 | $117 |
| W. L. Gore & Associates, Inc. | 1 | $101 |
| Stryker | 1 | $30 |
| Cardinal Health 200 LLC | 1 | $26 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Canon Medical Systems USA, Inc. | 1 | $24 |
| GE HealthCare | 1 | $18 |
| Chiesi USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$2,412
- EVOQUE$1,885
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,818
- SAPIEN 3 Ultra RESILIA$931
- MitraClip$892
- ONYX FRONTIER$810
- PASCAL$418
- HawkOne$316
- NUVISION ICE CATHETER$287
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$251
- Mitra Clip system$221
- THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM$165
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$155
- TRICLIP$154
- TherOx DS2 Console$154
- Catheter$154
- Downstream Cartridge$154
- IMBRUVICA$150
- Azur CX Detachable$136
- R2P MISAGO$136
How this compares
$50,983 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $80,382 |
| XareltoRivaroxaban | 33 | $37,151 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $1,613 |
| Metoprolol Succinate | 111 | $1,563 |
| Atorvastatin Calcium | 141 | $1,485 |
| Ezetimibe | 27 | $1,273 |
| Rosuvastatin Calcium | 78 | $1,237 |
| Valsartan | 27 | $876 |
| ClopidogrelClopidogrel Bisulfate | 41 | $732 |
| Bumetanide | 14 | $652 |
| Amlodipine Besylate | 66 | $497 |
| Lisinopril | 48 | $411 |
| Amiodarone Hcl | 12 | $332 |
| Carvedilol | 45 | $319 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 17 | $303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $121 | $80,38267 claims |
| Johnson & JohnsonXarelto | $118 | $37,15133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Lake Forest
- Owais Abdul KafiLake Forest$56K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.